Localization of CGRP receptor components and receptor binding sites in rhesus monkey brainstem: A detailed study using in situ hybridization, immunofluorescence, and autoradiography

Journal of Comparative Neurology

Volumn 524, Issue 1, 2016, Pages 90-118

  Eftekhari, Sajedeh ^a   Gaspar, Renee C ^b   Roberts, Rhonda ^b   Chen, Tsing Bau ^b   Zeng, Zhizhen ^b   Villarreal, Stephanie ^b   Edvinsson, Lars ^a   Salvatore, Christopher A ^b  

^a LUND UNIVERSITY   (Sweden)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Brainstem; CGRP; CGRP receptor antagonists; CLR; Primate; RAMP1; RRID:AB_142672; RRID:AB_2238799; RRID:AB_2314535; RRID:AB_2336928

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CALCITONIN RECEPTOR LIKE RECEPTOR; MESSENGER RNA; MK 3207; RECEPTOR ACTIVITY MODIFYING PROTEIN 1; UNCLASSIFIED DRUG; 2-(8-(3,5-DIFLUOROPHENYL)-10-OXO-6,9-DIAZASPIRO(4.5)DEC-9-YL)-N-(2'-OXO-1,1',2',3-TETRAHYDROSPIRO(INDENE-2,3'-PYRROLO(2,3-B)PYRIDIN)-5-YL)ACETAMIDE; FUSED HETEROCYCLIC RINGS; PROTEIN BINDING; RADIOPHARMACEUTICAL AGENT; SPIRO COMPOUND; TRITIUM;

ABDUCENS NUCLEUS; ANIMAL TISSUE; AREA POSTREMA; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BINDING SITE; BLOOD BRAIN BARRIER; BRAIN STEM; CELLULAR DISTRIBUTION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GRACILE NUCLEUS; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VITRO STUDY; INFERIOR OLIVE; MALE; MAMMILLARY BODY; MEDIAL LEMNISCUS; MEDIAN EMINENCE; MOTOR TRIGEMINAL NUCLEUS; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PINEAL BODY; PITUITARY STALK; PONTINE NUCLEUS; PONTINE RAPHE NUCLEUS; POSTERIOR HYPOTHALAMUS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAPHE NUCLEUS; RECEPTOR BINDING; RECEPTOR OCCUPANCY; RHESUS MONKEY; SIGNAL TRANSDUCTION; SPINAL CORD; TRIGEMINAL NUCLEUS; TROCHLEAR NUCLEUS; VAGUS NERVE; ANATOMY AND HISTOLOGY; ANIMAL; ANTAGONISTS AND INHIBITORS; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; VALIDATION STUDY;

ANIMALS; AUTORADIOGRAPHY; BICYCLO COMPOUNDS, HETEROCYCLIC; BRAIN STEM; CALCITONIN RECEPTOR-LIKE PROTEIN; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; IN SITU HYBRIDIZATION; MACACA MULATTA; MALE; PROTEIN BINDING; RADIOPHARMACEUTICALS; RECEPTOR ACTIVITY-MODIFYING PROTEIN 1; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; RNA, MESSENGER; SIGNAL TRANSDUCTION; SPINAL CORD; SPIRO COMPOUNDS; TRITIUM;

EID: 84948104998     PISSN: 00219967     EISSN: 10969861     Source Type: Journal    
DOI: 10.1002/cne.23828     Document Type: Article

References (91)

1. Afridi SK, Giffin NJ, Kaube H, Friston KJ, Ward NS, Frackowiak RS, Goadsby PJ. 2005a. A positron emission tomographic study in spontaneous migraine. Arch Neurol 62:1270-1275.
2. Afridi SK, Matharu MS, Lee L, Kaube H, Friston KJ, Frackowiak RS, Goadsby PJ. 2005b. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain 128:932-939.
3. Aggleton JP, Dumont JR, Warburton EC. 2011. Unraveling the contributions of the diencephalon to recognition memory: a review. Learn Mem 18:384-400.
4. Bahra A, Matharu MS, Buchel C, Frackowiak RS, Goadsby PJ. 2001. Brainstem activation specific to migraine headache. Lancet 357:1016-1017.
5. Barth SW, Riediger T, Lutz TA, Rechkemmer G. 2004. Peripheral amylin activates circumventricular organs expressing calcitonin receptor a/b subtypes and receptor-activity modifying proteins in the rat. Brain Res 997:97-102.
6. Bell IM, Gallicchio SN, Stump CA, Bruno JG, Fan H, Gantert LT, Hostetler ED, Kemmerer AL, McWherter M, Moore EL, Mosser SD, Purcell ML, Riffel K, Salvatore CA, Sanabria-Bohorquez S, Staas DD, White RB, Williams M, Zartman CB, Cook JJ, Hargreaves RJ, Kane SA, Graham SL, Selnick HG. 2013. [(11)C]MK-4232: The first positron emission tomography tracer for the calcitonin gene-related peptide receptor. ACS Med Chem Lett 4:863-868.
7. Bellamy JL, Cady RK, Durham PL. 2006. Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients. Headache 46:24-33.
8. Bohar Z, Fejes-Szabo A, Tar L, Varga H, Tajti J, Pardutz A, Vecsei L. 2013. Evaluation of c-Fos immunoreactivity in the rat brainstem nuclei relevant in migraine pathogenesis after electrical stimulation of the trigeminal ganglion. Neurol Sci 34:1597-1604.
9. Charles A. 2012. Migraine is not primarily a vascular disorder. Cephalalgia 32:431-432.
10. Charles A. 2013. Migraine: a brain state. Curr Opin Neurol 26:235-239.
11. Clarke IJ. 2015. Hypothalamus as an endocrine organ. Compr Physiol 5:217-253.
12. Claustrat B, Loisy C, Brun J, Beorchia S, Arnaud JL, Chazot G. 1989. Nocturnal plasma melatonin levels in migraine: a preliminary report. Headache 29:242-245.
13. Conti F, Sternini C. 1989. Calcitonin gene-related peptide (CGRP)-positive neurons and fibers in the cat periaqueductal grey matter. Somatosens Mot Res 6:497-511.
14. Cottrell GS, Roosterman D, Marvizon JC, Song B, Wick E, Pikios S, Wong H, Berthelier C, Tang Y, Sternini C, Bunnett NW, Grady EF. 2005. Localization of calcitonin receptor-like receptor and receptor activity modifying protein 1 in enteric neurons, dorsal root ganglia, and the spinal cord of the rat. J Comp Neurol 490:239-255.
15. Covenas R, Sanchez ML, Mangas A, Medina LE, Aguilar LA, Diaz-Cabiale Z, Narvaez JA. 2012. Mapping of CGRP in the alpaca diencephalon. J Chem Neuroanat 45-2:36-44.
16. de Souza E, Covenas R, Yi P, Aguilar LA, Lerma L, Andrade R, Mangas A, Diaz-Cabiale Z, Narvaez JA. 2008. Mapping of CGRP in the alpaca (Lama pacos) brainstem. J Chem Neuroanat 35:346-355.
17. Dellmann HD, Rodriguez EM. 1970. Herring bodies; an electron microscopic study of local degeneration and regeneration of neurosecretory axons. Z Zellforsch Mikrosk Anat 111 3:293-315.
18. Diener HC. 1997. Positron emission tomography studies in headache. Headache 37:622-625.
19. Diener HC, Barbanti P, Dahlof C, Reuter U, Habeck J, Podhorna J. 2011. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 31:573-584.
20. Dobolyi A, Irwin S, Makara G, Usdin TB, Palkovits M. 2005. Calcitonin gene-related peptide-containing pathways in the rat forebrain. J Comp Neurol 489:92-119.
21. Dolgin E. 2013. Antibody drugs set to revive flagging migraine target. Nat Rev Drug Discov 12:249-250.
22. Edvinsson L. 1987. Innervation of the cerebral circulation. Ann N Y Acad Sci 519:334-348.
23. Edvinsson L. 2011. Tracing neural connections to pain pathways with relevance to primary headaches. Cephalalgia 31:737-747.
24. Edvinsson L, Linde M. 2010. New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. Lancet 376:645-655.
25. Edvinsson L, Eftekhari S, Salvatore CA, Warfvinge K. 2010. Cerebellar distribution of calcitonin gene-related peptide (CGRP) and its receptor components calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1 (RAMP1) in rat. Mol Cell Neurosci 46:333-339.
26. Edvinsson L, Eftekhari S, Salvatore CA, Warfvinge K. 2011. Cerebellar distribution of calcitonin gene-related peptide (CGRP) and its receptor components calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1 (RAMP1) in rat. Mol Cell Neurosci 46:333-339.
27. Eftekhari S, Edvinsson L. 2011. Calcitonin gene-related peptide (CGRP) and its receptor components in human and rat spinal trigeminal nucleus and spinal cord at C1-level. BMC Neurosci 12:112.
28. Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, Edvinsson L. 2010. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience 169:683-696.
29. Eftekhari S, Salvatore CA, Gaspar RC, Roberts R, O'Malley S, Zeng Z, Edvinsson L. 2013. Localization of CGRP receptor components, CGRP, and receptor binding sites in human and rhesus cerebellar cortex. Cerebellum 12:937-949.
30. Eftekhari S, Salvatore CA, Johansson S, Chen TB, Zeng Z, Edvinsson L. 2015. Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier. Brain Res 1600:93-109.
31. Elvidge S. 2014. Anti-CGRP antibodies for migraine turn industry heads. Nat Biotechnol 32:707.
32. Evans BN, Rosenblatt MI, Mnayer LO, Oliver KR, Dickerson IM. 2000. CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors. J Biol Chem 275:31438-31443.
33. Garcia-Sevilla JA, Ferrer-Alcon M, Martin M, Kieffer BL, Maldonado R. 2004. Neurofilament proteins and cAMP pathway in brains of mu-, delta- or kappa-opioid receptor gene knock-out mice: effects of chronic morphine administration. Neuropharmacology 46:519-530.
34. Goadsby PJ. 2007. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med 13:39-44.
35. Goadsby PJ, Edvinsson L. 1993. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48-56.
36. Goadsby PJ, Edvinsson L, Ekman R. 1990. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28:183-187.
37. Goadsby PJ, Charbit AR, Andreou AP, Akerman S, Holland PR. 2009. Neurobiology of migraine. Neuroscience 161:327-341.
38. Gulbenkian S, Uddman R, Edvinsson L. 2001. Neuronal messengers in the human cerebral circulation. Peptides 22:995-1007.
39. Hargreaves RJ, Shepheard SL. 1999. Pathophysiology of migraine-new insights. Can J Neurol Sci 26(suppl 3):S12-19.
40. Headache Classification Subcommittee of the International Headache Society. 2004. The International Classification of Headache Disorders, 2nd ed. Cephalalgia 24(suppl 1):9-160.
41. Hewitt DJ, Aurora SK, Dodick DW, Goadsby PJ, Ge YJ, Bachman R, Taraborelli D, Fan X, Assaid C, Lines C, Ho TW. 2011. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 31:712-722.
42. Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Assaid C, Lines C, Koppen H, Winner PK. 2008. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372:2115-2123.
43. Horsburgh A, Massoud TF. 2013. The circumventricular organs of the brain: conspicuity on clinical 3T MRI and a review of functional anatomy. Surg Radiol Anat 35:343-349.
44. Hostetler ED, Joshi AD, Sanabria-Bohorquez S, Fan H, Zeng Z, Purcell M, Gantert L, Riffel K, Williams M, O'Malley S, Miller P, Selnick HG, Gallicchio SN, Bell IM, Salvatore C, Kane SA, Li CC, Hargreaves R, de Groot T, Bormans G, Van Hecken A, Derdelinckx I, de Hoon J, Reynders T, Declercq R, De Lepeleire I, Kennedy WD, Blanchard R, Marcantonio EE, Sur C, Cook JJ, van Laere K, Evelhoch JL. 2013. In vivo quantification of calcitonin gene-related peptide (CGRP) receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography (PET) tracer [11C]MK-4232. J Pharmacol Exp Ther 347:478-486.
45. Inagaki S, Kito S, Kubota Y, Girgis S, Hillyard CJ, MacIntyre I. 1986. Autoradiographic localization of calcitonin gene-related peptide binding sites in human and rat brains. Brain Res 374:287-298.
46. Johnston MM, Jordan SE, Charles AC. 2013. Pain referral patterns of the C1 to C3 nerves: Implications for headache disorders. Ann Neurol 74:145-148.
47. Just S, Arndt K, Doods H. 2005. The role of CGRP and nicotinic receptors in centrally evoked facial blood flow changes. Neurosci Lett 381:120-124.
48. Knight YE, Goadsby PJ. 2001. The periaqueductal grey matter modulates trigeminovascular input: a role in migraine? Neuroscience 106:793-800.
49. Kresse A, Jacobowitz DM, Skofitsch G. 1995. Detailed mapping of CGRP mRNA expression in the rat central nervous system: comparison with previous immunocytochemical findings. Brain Res Bull 36:261-274.
50. Lakhan SE, Avramut M, Tepper SJ. 2013. Structural and functional neuroimaging in migraine: insights from 3 decades of research. Headache 53:46-66.
51. Lennerz JK, Ruhle V, Ceppa EP, Neuhuber WL, Bunnett NW, Grady EF, Messlinger K. 2008. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol 507:1277-1299.
52. Liu S. 2004. Peptidergic innervation in pars distalis of the human anterior pituitary. Brain Res 1008:61-68.
53. Ma W, Chabot JG, Powell KJ, Jhamandas K, Dickerson IM, Quirion R. 2003. Localization and modulation of calcitonin gene-related peptide-receptor component protein-immunoreactive cells in the rat central and peripheral nervous systems. Neuroscience 120:677-694.
54. Maniyar FH, Sprenger T, Monteith T, Schankin C, Goadsby PJ. 2014. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain 137:232-241.
55. Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ. 2014. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 34:114-125.
56. Martin JH. 2003. Neuroanatomy. New York, NY: McGraw-Hill.
57. Mauskop A. 2005. Vagus nerve stimulation relieves chronic refractory migraine and cluster headaches. Cephalalgia 25:82-86.
58. May A. 2003. Headache: lessons learned from functional imaging. Br Med Bull 65:223-234.
59. May A. 2013. Pearls and pitfalls: neuroimaging in headache. Cephalalgia 33:554-565.
60. May A, Bahra A, Buchel C, Frackowiak RS, Goadsby PJ. 1998. Hypothalamic activation in cluster headache attacks. Lancet 352:275-278.
61. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM. 1998. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393:333-339.
62. Nowicki M, Wojtkiewicz J, Lewczuk B, Kosacka J, Majewski M, Przybylska-Gornowicz B. 2007. Peptidergic and nitrergic innervation of the pineal gland in the domestic pig: an immunohistochemical study. Anat Histol Embryol 36:311-320.
63. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM. 2004. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104-1110.
64. Paxinos G, Huang X-F, Toga AW. 2000. The rhesus monkey brain in stereotaxic coordinates. Waltham, MA: Academic Press.
65. Peres MF. 2005. Melatonin, the pineal gland and their implications for headache disorders. Cephalalgia 25:403-411.
66. Peres MF, Sanchez del Rio M, Seabra ML, Tufik S, Abucham J, Cipolla-Neto J, Silberstein SD, Zukerman E. 2001. Hypothalamic involvement in chronic migraine. J Neurol Neurosurg Psychiatry 71:747-751.
67. Poyner DR. 1992. Calcitonin gene-related peptide: multiple actions, multiple receptors. Pharmacol Ther 56:23-51.
68. Raskin NH, Hosobuchi Y, Lamb S. 1987. Headache may arise from perturbation of brain. Headache 27:416-420.
69. Reiter RJ. 1991. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 12:151-180.
70. Reuss S. 1999. Trigeminal innervation of the mammalian pineal gland. Microsc Res Tech 46:305-309.
71. Salvatore CA, Moore EL, Calamari A, Cook JJ, Michener MS, O'Malley S, Miller PJ, Sur C, Williams DL Jr, Zeng Z, Danziger A, Lynch JJ, Regan CP, Fay JF, Tang YS, Li CC, Pudvah NT, White RB, Bell IM, Gallicchio SN, Graham SL, Selnick HG, Vacca JP, Kane SA. 2010. Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. J Pharmacol Exp Ther 333:152-160.
72. Sexton PM, McKenzie JS, Mason RT, Moseley JM, Martin TJ, Mendelsohn FA. 1986. Localization of binding sites for calcitonin gene-related peptide in rat brain by in vitro autoradiography. Neuroscience 19:1235-1245.
73. Sixt ML, Messlinger K, Fischer MJ. 2009. Calcitonin gene-related peptide receptor antagonist olcegepant acts in the spinal trigeminal nucleus. Brain 132:3134-3141.
74. Skofitsch G, Jacobowitz DM. 1985a. Calcitonin gene-related peptide: detailed immunohistochemical distribution in the central nervous system. Peptides 6:721-745.
75. Skofitsch G, Jacobowitz DM. 1985b. Quantitative distribution of calcitonin gene-related peptide in the rat central nervous system. Peptides 6:1069-1073.
76. Smith GS, Savery D, Marden C, Lopez Costa JJ, Averill S, Priestley JV, Rattray M. 1994. Distribution of messenger RNAs encoding enkephalin, substance P, somatostatin, galanin, vasoactive intestinal polypeptide, neuropeptide Y, and calcitonin gene-related peptide in the midbrain periaqueductal grey in the rat. J Comp Neurol 350:23-40.
77. Stankewitz A, Voit HL, Bingel U, Peschke C, May A. 2010. A new trigemino-nociceptive stimulation model for event-related fMRI. Cephalalgia 30:475-485.
78. Stankewitz A, Aderjan D, Eippert F, May A. 2011. Trigeminal nociceptive transmission in migraineurs predicts migraine attacks. J Neurosci 31:1937-1943.
79. Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner T, Zwart JA. 2007. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 27:193-210.
80. Summ O, Charbit AR, Andreou AP, Goadsby PJ. 2010. Modulation of nocioceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus. Brain 133:2540-2548.
81. Tajti J, Uddman R, Edvinsson L. 2001. Neuropeptide localization in the "migraine generator" region of the human brainstem. Cephalalgia 21:96-101.
82. Ter Horst GJ, Meijler WJ, Korf J, Kemper RH. 2001. Trigeminal nociception-induced cerebral Fos expression in the conscious rat. Cephalalgia 21:963-975.
83. Toglia JU. 2001. Melatonin: a significant contributor to the pathogenesis of migraine. Med Hypotheses 57:432-434.
84. Ueda T, Ugawa S, Saishin Y, Shimada S. 2001. Expression of receptor-activity modifying protein (RAMP) mRNAs in the mouse brain. Brain Res Mol Brain Res 93:36-45.
85. Van Rossum D, Menard DP, Fournier A, St-Pierre S, Quirion R. 1994. Binding profile of a selective calcitonin gene-related peptide (CGRP) receptor antagonist ligand, [125I-Tyr]hCGRP8-37, in rat brain and peripheral tissues. J Pharmacol Exp Ther 269:846-853.
86. Wang QP, Nakai Y. 1994. The dorsal raphe: an important nucleus in pain modulation. Brain Res Bull 34:575-585.
87. Weiller C, May A, Limmroth V, Juptner M, Kaube H, Schayck RV, Coenen HH, Diener HC. 1995. Brain stem activation in spontaneous human migraine attacks. Nat Med 1:658-660.
88. Veloso F, Kumar K, Toth C. 1998. Headache secondary to deep brain implantation. Headache 38:507-515.
89. Vermeersch S DHJ, De Saint-Huber B, Derdelinckx I, Porters K, Stekers M, Serdons K, Bormans G, Reynders T, Declercq R, De Lepeleire I, Kennedy W.D, Blancard R, Marcantonio E, Hargreaves R, Li C-C, Sanabria S, Hosteöer E, Joshi A, Evelhoch J, Van Laere K. 2012. PET imaging in healty subjects and migraineurs suggests CGRP receptor antagonists do not have to act centrally to achieve clinical efficacy. European Headache and Migraine Trust International Congress, London, 20-23 September 2012 Poster number LB08.
90. Yin W, Gore AC. 2010. The hypothalamic median eminence and its role in reproductive aging. Ann N Y Acad Sci 1204:113-122.
91. Zhang Z, Winborn CS, Marquez de Prado B, Russo AF. 2007. Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J Neurosci 27:2693-2703.